You also missed the extra intellectual property rights for pharmaceuticals in Addendum II. Those are controversial, and in the previous draft, were in the main document. Now they've been moved down to an addendum and are different for different countries.
There's also *
[US/JP propose; CL/MY/PE/SG/VN/BN/AU/NZ/CA/MX oppose: 2bis. For greater certainty, a Party may not deny a patent solely on the basis that the product did not result in an enhanced efficacy of the known product when the applicant has set forth distinguishing features establishing that the invention is new, involves an inventive step, and is capable of industrial application.]*
That's a gimme for Big Pharma's "me too" drugs, where it's no better, but slightly different. Clarinex is an example.
There's also * [US/JP propose; CL/MY/PE/SG/VN/BN/AU/NZ/CA/MX oppose: 2bis. For greater certainty, a Party may not deny a patent solely on the basis that the product did not result in an enhanced efficacy of the known product when the applicant has set forth distinguishing features establishing that the invention is new, involves an inventive step, and is capable of industrial application.]*
That's a gimme for Big Pharma's "me too" drugs, where it's no better, but slightly different. Clarinex is an example.